Search
AI biotechnology company Insilico Medicine plans to raise approximately HK$2.28 billion in Hong Kong IPO
2025-12-18 /
Read about 0 minute
Author：小编
According to the announcement submitted by Insilico Medicine to the Hong Kong Stock Exchange, the company plans to issue approximately 95 million shares in Hong Kong at a price of HK$24.05 per share, aiming to raise approximately HK$2.28 billion (equivalent to US$293 million), and is scheduled to officially list on December 30. The joint sponsors for this listing are Morgan Stanley, CICC, and GF Securities. Insilico Medicine is an AI-driven biotechnology company that accelerates the drug discovery process through its Pharma.AI platform.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
